Trial Profile

A randomized, open-label, comparative evaluation of conversion from calcineurin inhibitors to sirolimus versus continued use of calcineurin inhibitors in renal allograft recipients

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary) ; Ciclosporin; Tacrolimus
Indications Renal transplant rejection
Focus Therapeutic Use
Acronyms CONVERT
Sponsors Wyeth

Most Recent Events

17 Mar 2020 Results pooled analysis from the data of 3 clinical trials of Sirolimus assessing rates of TEAEs, serious AEs (SAEs), and discontinuations, published in the Transplantation Proceedings
10 Apr 2014 Data cleaning project 4: Calcineurin inhibitors deleted from descriptors.
18 May 2010 Actual end date (May 2008) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com